摘要
原发性肝癌(HCC)是消化道常见的恶性肿瘤,虽然在过去30年,中国的HCC发病率及病死率有呈现下降的趋势,但从世界范围内来讲,中国仍然是HCC大国。在HCC总体生存率得到提高的同时,中晚期HCC患者的预后仍然不尽人意,中晚期HCC治疗形势严峻。最近3年,一系列针对中晚期HCC的药物及治疗策略如雨后春笋般展现出来,极大的改善了患者的预后。笔者从目前取得阶段性成就的几大领域总结目前中晚期HCC的治疗进展。
Hepatocellular carcinoma(HCC) is a common malignant tumor of the digestive tract. Although the morbidity and mortality rates of HCC have been decreasing over the past 30 years in our country, China is still the country most afflicted by HCC worldwide. Despite the significant improvement in overall survival rate of HCC, the prognosis of patients with advanced HCC is still unsatisfactory and its treatment situation is very severe. In latest three years, a series of drugs and treatment strategies for advanced HCC have sprung up, which greatly improved the prognosis of the patients. Here, the authors summarize the progress in the treatment of advanced HCC in several fields with notable achievements.
作者
奉建祁
王志明
FENG Jianqi;WANG Zhiming(Department of Liver Surgery,Xiangya Hospital,Central South University,Changsha 410008,China)
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2021年第7期847-857,共11页
China Journal of General Surgery
关键词
癌
肝细胞
免疫疗法
分子靶向治疗
药物疗法
联合
综述
Carcinoma,Hepatocellular
Immunotherapy
Molecular Targeted Therapy
Drug Therapy
Combination
Review
